Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study

Lancet

Volumn 359, Issue 9309, 2002, Pages 824-830

  Zander, Mette ^a,b   Madsbad, Sten ^b   Madsen, Jan Lysgaard ^b   Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; FRUCTOSAMINE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A; INSULIN;

ADULT; APPETITE; ARTICLE; BODY WEIGHT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 0037045845     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07952-7     Document Type: Article

References (35)

1. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Glucagon-like peptide-1 7-36: A physiological incretin in man
4. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39
5. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes
6. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
7. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)- (7-36) amide in type 2 (noninsulin-dependent) diabetic patients
8. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
9. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats
10. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
11. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
12. Glucose clamp technique: A method for quantifying insulin secretion and resistance
13. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies
14. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
15. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
16. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
17. Glucagon-like peptide-1 (GLP-1): A trial of treatment in non-insulin-dependent diabetes mellitus
18. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
19. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: Dose- response-relationships
20. Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy
21. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM
22. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men
23. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity
24. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM
25. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes
26. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
27. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes
28. Glucose toxicity
29. Intensive conventional insulin therapy for type II diabetes: Metabolic effects during a 6-mo outpatient trial
30. Assessment of hepatic insulin action in obese type 2 diabetic patients
31. Banting lecture 1990: Beta-cells in type II diabetes mellitus
32. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans
33. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes
34. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
35. Insulin signal transduction in skeletal muscle from glucose intolerant relatives of type 2 diabetic patients